Evidence map›Paper›PMID 24900663›Full record

ArticleACS medicinal chemistry letters2013

Immune-Stimulatory Dinucleotide at the 5'-End of Oligodeoxynucleotides Is Critical for TLR9-Mediated Immune Responses.

Mallikarjuna R Putta, Lakshmi Bhagat, Daqing Wang, Fu-Gang Zhu, Ekambar R Kandimalla, Sudhir Agrawal

Abstract read
In one paragraph

Article in ACS medicinal chemistry letters, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.1field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Review
  3. Biomaterials for vaccine-based cancer immunotherapy.Journal of controlled release : official journal of the Controlled Release Society · 2018
    Review
  4. Investigations into the efficacy of multi-component cocaine vaccines.Bioorganic & medicinal chemistry letters · 2018
    Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Mallikarjuna R PuttaIdera Pharmaceuticals, Inc. , 167 Sidney Street, Cambridge, Massachusetts 02139, United States.
Lakshmi BhagatIdera Pharmaceuticals, Inc. , 167 Sidney Street, Cambridge, Massachusetts 02139, United States.
Daqing WangIdera Pharmaceuticals, Inc. , 167 Sidney Street, Cambridge, Massachusetts 02139, United States.
Fu-Gang ZhuIdera Pharmaceuticals, Inc. , 167 Sidney Street, Cambridge, Massachusetts 02139, United States.
Ekambar R KandimallaIdera Pharmaceuticals, Inc. , 167 Sidney Street, Cambridge, Massachusetts 02139, United States.
Sudhir AgrawalIdera Pharmaceuticals, Inc. , 167 Sidney Street, Cambridge, Massachusetts 02139, United States.
Idera Pharmaceuticals (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Oligodeoxynucleotides (ODNs) containing a CpG or certain synthetic dinucleotides, referred to as immune-stimulatory dinucleotides, induce Toll-like receptor 9 (TLR9)-mediated immune responses. Chemical modifications such as 2'-O-methylribonucleotides incorporated adjacent to the immune-stimulatory dinucleotide on the 5'-side abrogate TLR9-mediated immune responses. In this study, we evaluated the effect of the location of immune-stimulatory dinucleotides in ODNs on TLR9-mediated immune responses. We designed and synthesized ODNs with two immune-stimulatory dinucleotides, one placed toward the 5'-end region and the other toward the 3'-end region, incorporated 2'-O-methylribonucleotides selectively preceding the 5'- or 3'-immune-stimulatory dinucleotide or both, and studied TLR9-mediated immune responses of these compounds in cell-based assays and in vivo in mice. These studies showed that an immune-stimulatory dinucleotide located closer to the 5'-end is critical for and dictates TLR9-mediated immune responses. These studies provide insights for the use of ODNs when employed as TLR9 agonists and antagonists or antisense agents.

Indexed as

immune stimulationimmune-stimulatory dinucleotideNF-κBoligodeoxynucleotidesToll-like receptor 9

Identifiers

PMID24900663
PMCPMC4027476
OpenAlexW1998336070

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.